Zacks Equity Research

InMode (INMD) Stock Moves -0.23%: What You Should Know | Zacks | 2/8/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article In the latest trading session, InMode ( INMD - Free Report ) closed at $42.81, marking a -0.23% move from the previous day. This change was narrower than the S&P 500’s 0.54% loss on the day. Elsewhere, the Dow lost 0.94%, while the …

Omnicell (OMCL) Misses Q4 Earnings Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Omnicell ( OMCL - Free Report ) came out with quarterly earnings of $0.77 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This …

Follow Zacks Equity Research:    

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Seattle Genetics ( SGEN - Free Report ) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago. These figures are adjusted for non …

Enanta Pharmaceuticals (ENTA) Q1 Earnings Top Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Enanta Pharmaceuticals ( ENTA - Free Report ) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $1.25 per share a year ago. These figures are adjusted for non-recurring items …

Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics ( MYGN - Free Report ) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items …

Encompass Health (EHC) Q4 Earnings and Revenues Lag Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Encompass Health ( EHC - Free Report ) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items …

Epizyme (EPZM) Stock Sinks As Market Gains: What You Should Know | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Epizyme ( EPZM - Free Report ) closed at $21.78 in the latest trading session, marking a -0.5% move from the prior day. This move lagged the S&P 500’s daily gain of 0.33%. At the same time, the Dow added 0.3%, and the …

Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article In the latest trading session, Nektar Therapeutics ( NKTR - Free Report ) closed at $22.81, marking a -0.52% move from the previous day. This change lagged the S&P 500’s 0.33% gain on the day. At the same time, the Dow added 0.3 …

SmileDirectClub (SDC) Stock Sinks As Market Gains: What You Should Know | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article In the latest trading session, SmileDirectClub ( SDC - Free Report ) closed at $14.15, marking a -0.04% move from the previous day. This change lagged the S&P 500’s 0.33% gain on the day. At the same time, the Dow added 0.3%, and …

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article In the latest trading session, CRISPR Therapeutics AG ( CRSP - Free Report ) closed at $54.33, marking a -0.93% move from the previous day. This change lagged the S&P 500’s 0.33% gain on the day. At the same time, the Dow added …

Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article In the latest trading session, Tilray, Inc. ( TLRY - Free Report ) closed at $17.78, marking a +1.08% move from the previous day. This move outpaced the S&P 500’s daily gain of 0.33%. Meanwhile, the Dow gained 0.3%, and the Nasdaq, a …

Natus Medical (NTUS) Misses Q4 Earnings Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research Zacks Equity Research Natus Medical ( NTUS - Free Report ) came out with quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.13%. A quarter ago, it …

Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research Zacks Equity Research Ligand Pharmaceuticals ( LGND - Free Report ) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $1.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.41%. A quarter ago, it …

Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4 | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research Zacks Equity Research Pacific Biosciences of California ( PACB - Free Report ) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 100%. A quarter ago …

LeMaitre Vascular (LMAT) Q4 Earnings Match Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research Zacks Equity Research LeMaitre Vascular ( LMAT - Free Report ) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this medical device maker would post earnings of …

Meridian Bioscience (VIVO) Beats Q1 Earnings Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Meridian Bioscience ( VIVO - Free Report ) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items …

Should You Buy Molina (MOH) Ahead of Earnings? | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Investors are always looking for stocks that are poised to beat at earnings season and Molina Healthcare, Inc. ( MOH - Free Report ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for …

AIT Therapeutics, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article AIT Therapeutics, Inc. ( XAIR - Free Report ) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for …

Company News for Feb 7, 2020 | Zacks | 2/7/2020

Company News for Feb 7, 2020 Zacks Equity Research You follow Corporate Summary - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Bristol-Myers Squibb Company ( BMY - Free Report ) rose 2.3% after the company reported fourth-quarter earnings of $1.22 per share, beating the Zacks Consensus Estimate of $0.88 Shares of Cigna Corporation ( CI - Free …

Is Cardinal Health (CAH) a Great Value Stock Right Now? | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and …

Committee for Medicinal Products for Human Use

Alnylam’s (ALNY) Q4 Earnings Miss Estimates, Sales Beat | Zacks | 2/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Alnylam Pharmaceuticals, Inc. ( ALNY - Free Report ) incurred a loss … the treatment of AHP in adolescents and adults from the Committee for Medicinal Products for Human Use (CHMP) in the EU. Adjusted research and development (R&D) expenses increased 41% from the year-ago period …

Bristol-Myers’ Opdivo-Yervoy NSCLC Application in EU Withdrawn | Zacks | 2/3/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Bristol-Myers Squibb Company ( BMY - Free Report ) announced the … whose tumors expressed PD-L1 ≥1% Per the company, Europe’s Committee for Medicinal Products for Human Use (CHMP) stated that it was not possible to assess the data provided by the company because of “multiple …

Clinical Research

What’s in the Offing for LabCorp’s (LH) Earnings in Q4? | Zacks | 2/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Laboratory Corporation of America Holdings ( LH - Free Report ) also … fourth quarter. The transaction provides Covance with better global non-clinical research capabilities while maintaining access to bigger research models and services through a multi-year renewable supply agreement. Overall, for 2019, LabCorp expects year …

Here’s Why You Should Hold on to Nevro (NVRO) Stock for Now | Zacks | 2/4/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Nevro Corp. ( NVRO - Free Report ) is well-poised for … Per management, the primary competitive factors include company brand recognition, clinical research leadership, pricing and reimbursement. Factors to Bolster Nevro Nevro continues to benefit from sturdy international foothold, thereby driving overall performance. Per management, growth …

Digital Health

Here’s Why You Should Add ResMed (RMD) to Your Portfolio | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article ResMed Inc. ( RMD - Free Report ) has been gaining from robust segmental and international growth. The company’s focus on core sleep apnea franchise, digital health technology and international markets is expected to further propel the rally.Over the past year, shares of the Zacks Rank 2 …

ResMed (RMD) Rides on New Product Portfolio, SaaS Growth | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article On Feb 5, 2020, we issued an updated research … quarter under review grew in double digits. ResMed’s focus on digital health technology instils investors’ optimism. Of late, ResMed has been focusing on digital health technology. The Brightree and MatrixCare software systems are significantly adding …

Telehealth

Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know | Zacks | 2/5/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teladoc ( TDOC - Free Report ) closed the most … heavy index, added 0.43%. Coming into today, shares of the telehealth services provider had gained 24.99% in the past month. In that same time, the Medical sector gained 2.11%, while the S&P 500 gained …

Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know | Zacks | 1/31/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teladoc ( TDOC - Free Report ) closed at $104.75 … Nasdaq gained 0.26%. Prior to today’s trading, shares of the telehealth services provider had gained 23.6% over the past month. This has outpaced the Medical sector’s loss of 1.25% and the S&P 500’s …

Home Health

DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know | Zacks | 1/17/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article DaVita HealthCare ( DVA - Free Report ) closed at … expected earnings growth rate into account. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 2.59 as of yesterday’s close. The Medical - Outpatient and Home Healthcare industry is part of …

Why Encompass Health Corporation (EHC) is Poised to Beat Earnings Estimates Again | Zacks | 1/16/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Encompass Health Corporation ( EHC - Free Report ) , which belongs to the Zacks Medical - Outpatient and Home Healthcare …

Home Healthcare

DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know | Zacks | 1/17/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article DaVita HealthCare ( DVA - Free Report ) closed at … expected earnings growth rate into account. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 2.59 as of yesterday’s close. The Medical - Outpatient and Home Healthcare industry is part of …

Why Encompass Health Corporation (EHC) is Poised to Beat Earnings Estimates Again | Zacks | 1/16/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Encompass Health Corporation ( EHC - Free Report ) , which belongs to the Zacks Medical - Outpatient and Home Healthcare

Biotech

Medicines Company Posts Full Inclisiran Data From ASCVD Study | Zacks | 11/18/2019

Medicines Company Posts Full Inclisiran Data From ASCVD Study Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More … Rank 3 (Hold) stock. A better-ranked stock in the biotech sector is Anika Therapeutics Inc. ( ANIK - Free Report ) , sporting a Zacks Rank 1 (Strong Buy). You can see the complete list of today’s Zacks …

Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion | Zacks | 11/15/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Amarin Corporation plc ( AMRN - Free Report ) announced that the … Rank 2 (Buy) stock. A better-ranked stock in the biotech sector is Anika Therapeutics Inc. ( ANIK - Free Report ) , sporting a Zacks Rank 1 (Strong Buy). You can see the complete list of today’s Zacks …

Medicare

Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings | Zacks | 11/18/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Humana Inc. ( HUM - Free Report ) hit a fresh 52-week high of $340.48 on Nov 15, before closing the day at $335.55. Impressive earnings performance in the third quarter and solid Medicare business contributed to this rally.Over the past year, the Zacks …

Insulet (PODD) Hits a 52-Week High: What’s Driving the Stock? | Zacks | 11/15/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article On Nov 14, shares of Insulet Corporation ( PODD - Free … the company successfully expanded the Omnipod DASH coverage for commercial, Medicare and Medicaid beneficiaries. By the end of the third quarter, the coverage was expanded to more than 50% of all Medicare beneficiaries. Gross profit …

Personal Care

Amedisys Partners With nVoq to Improve Clinician Experience | Zacks | 11/18/2019

Amedisys Partners With nVoq to Improve Clinician Experience Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … to establish a partnership between Amedisys’ home-health centers and personal care agencies, helping caregivers of patients to coordinate using ClearCare.Amedisys finalized an acquisition deal with RoseRock Healthcare (a hospice care provider in Tulsa, OK …

Rockwell Automation to Gain on Products and Acquisitions | Zacks | 11/15/2019

Rockwell Automation to Gain on Products and Acquisitions Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … industries (which include Food & Beverage, Life Sciences and Household and Personal Care, among others) are expected to be up in low single-digits driven by growth in Life Sciences, Food & beverage, and Tire markets.Uncertainty with …

Medicare Advantage

Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings | Zacks | 11/18/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Humana Inc. ( HUM - Free Report ) hit a … by 9.8%. This upside can primarily be attributed to its Medicare Advantage (MA) membership growth and higher revenues.The company’s Medicare business has been performing strongly over the last many quarters. Impressive growth in the Medicare …

CVS Health’s New Plans With Aetna May Improve Health Outcomes | MSN | 11/15/2019

Zacks Equity Research 14 hrs ago Zacks Equity Research CVS, with its newly-acquired Aetna business, developed a Social Isolation Index to assess each Medicare beneficiary’s risk of social isolation. The mentioned index is based on claims data and multifaceted data on social determinants of health, and will help in identifying high-risk candidates. The company’s outreach program, Resources For Living, which is accessible to all members of Aetna Medicare …

Eli Lilly

Incyte (INCY) to Report Q4 Earnings: What’s in the Cards? | Zacks | 2/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Incyte Corporation ( INCY - Free Report ) is scheduled to report … the company’s revenue growth, Iclusig sales and Olumiant royalties from Eli Lilly ( LLY - Free Report ) also contribute to the top line. Hence, these are likely to have contributed significantly to the company’s revenues in the …

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? | Zacks | 2/5/2020

You follow Sector ETF - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Launched on 06/23/2005, the Invesco Dynamic Biotechnology & Genome ETF … sector–about 100% of the portfolio. Looking at individual holdings, Eli Lilly & Co ( LLY - Free Report ) accounts for about 5.60% of total assets, followed by Bristol-Myers Squibb Co ( BMY - Free Report ) and Johnson & Johnson …

Gilead

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences | 2/7/2020

Read More Hide Full Article For Immediate Release Chicago, IL – February 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Exxon Mobil ( XOM - Free Report ) , Chevron ( CVX - Free Report ) , International Business Machines ( IBM - Free Report ) , Gilead Sciences ( GILD - Free Report …

Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates | Zacks | 2/6/2020

… Also, IBM’s time-consuming business model transition to cloud is a headwind. Other noteworthy reports we are featuring today include Gilead Sciences ( GILD ), Illinois Tool Works ( ITW ) and Edwards Lifesciences ( EW ). More Stock News: This … Sheraz Mian Director of Research Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes …

AmerisourceBergen

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates | Zacks | 2/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics, Inc . ( MYGN - Free Report ) reported adjusted earnings … Corporation ( SYK - Free Report ) , Accuray Incorporated ( ARAY - Free Report ) and AmerisourceBergen ( ABC - Free Report ) . You can see the complete list of today’s Zacks 1 Rank (Strong Buy) stocks here . Stryker delivered fourth-quarter 2019 adjusted …

Cerner (CERN) Earnings and Revenues Beat Estimates in Q4 | Zacks | 2/5/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Cerner Corporation ( CERN - Free Report ) reported fourth-quarter 2019 … Corporation ( SYK - Free Report ) , Accuray Incorporated ( ARAY - Free Report ) and AmerisourceBergen Corporation ( ABC - Free Report ) . You can see the complete list of today’s Zacks 1 Rank (Strong Buy) stocks here . Stryker delivered fourth-quarter 2019 …

Myriad Genetics

Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics ( MYGN - Free Report ) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items …

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates | Zacks | 2/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics, Inc . ( MYGN - Free Report ) reported adjusted earnings per share (EPS) of 23 cents in the second quarter of fiscal 2020, down 39.5% year over year. Adjusted EPS also lagged the Zacks Consensus Estimate by 25.8%. Sharp year-over-year decline in revenues …

CVS Health

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Cardinal Health, Inc. ( CAH - Free Report ) reported second-quarter … review. Apart from these, the company’s extension of agreements with CVS Health, collaboration with PANTHERx Specialty Pharmacy and buyout of mscripts raise optimism. The company raised fiscal year 2020 outlook, driven by the aforementioned improved …

CVS Health (CVS) Gains But Lags Market: What You Should Know | Zacks | 2/5/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article CVS Health ( CVS - Free Report ) closed at $67.88 in the latest trading session, marking a +1.42% move from the prior day. The stock lagged the S&P 500’s daily gain of 1.5%. Elsewhere, the Dow gained 1.44%, while the tech-heavy …

CVS

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Cardinal Health, Inc. ( CAH - Free Report ) reported second-quarter … review. Apart from these, the company’s extension of agreements with CVS Health, collaboration with PANTHERx Specialty Pharmacy and buyout of mscripts raise optimism. The company raised fiscal year 2020 outlook, driven by the aforementioned improved …

CVS Health (CVS) Gains But Lags Market: What You Should Know | Zacks | 2/5/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article CVS Health ( CVS - Free Report ) closed at $67.88 in the latest trading session, marking a +1.42% move from the prior day. The stock lagged the S&P 500’s daily gain of 1.5%. Elsewhere, the Dow gained 1.44%, while the tech-heavy …

Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know | Zacks | 2/6/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teva Pharmaceutical Industries Ltd. ( TEVA - Free Report ) closed at $12.10 in the latest trading session, marking a +0.33% move from the prior day. This change lagged the S&P 500’s 1.13% gain on the day. At the same time, the Dow …

Teva’s Two Pivotal Studies on Ajovy in Japan Meet Goal | Zacks | 2/4/2020

Teva’s Two Pivotal Studies on Ajovy in Japan Meet Goal Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teva Pharmaceutical Industries Limited ( TEVA - Free Report ) announced positive results from two phase II/III studies on its new migraine drug Ajovy in patients with chronic and episodic migraines in Japan …

Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know | Zacks | 2/6/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teva Pharmaceutical Industries Ltd. ( TEVA - Free Report ) closed at $12.10 in the latest trading session, marking a +0.33% move from the prior day. This change lagged the S&P 500’s 1.13% gain on the day. At the same time, the Dow …

Teva’s Two Pivotal Studies on Ajovy in Japan Meet Goal | Zacks | 2/4/2020

Teva’s Two Pivotal Studies on Ajovy in Japan Meet Goal Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teva Pharmaceutical Industries Limited ( TEVA - Free Report ) announced positive results from two phase II/III studies on its new migraine drug Ajovy in patients with chronic and episodic migraines in Japan …

Abiomed

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article ABIOMED, Inc. ( ABMD - Free Report ) reported third-quarter fiscal 2020 earnings per share (EPS) of $1.51, outpacing the Zacks Consensus Estimate of $1.09. The figure surged 55.7% year over year. The Zacks Rank 4 (Sell) company’s revenues came in at $221.6 million, which lagged …

Haemonetics

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand | Zacks | 2/5/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Haemonetics Corporation ( HAE - Free Report ) delivered adjusted earnings per share (EPS) of 94 cents in the third quarter of fiscal 2020, reflecting 49.2% year-over-year growth. The bottom line also surpassed the Zacks Consensus Estimate by 23.7%.On a GAAP (reported) basis, net …

Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates | Zacks | 2/4/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Haemonetics ( HAE - Free Report ) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This …

Legg Mason

The Zacks Analyst Blog Highlights: TerraForm Power, M.D.C. Holdings, AllianceBernstein, Legg Mason and Community Healthcare Trust | 2/3/2020

Read More Hide Full Article For Immediate Release Chicago, IL – February 3, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: TerraForm Power Inc. ( TERP - Free Report ) , M.D.C. Holdings Inc. ( MDC - Free Report ) , AllianceBernstein Holding L.P. ( AB - Free Report ) , Legg Mason

Legg Mason AUM Rises in October, Fixed Income Inflows Recorded | Zacks | 11/13/2019

Legg Mason AUM Rises in October, Fixed Income Inflows Recorded Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Legg Mason Inc. ( LM - Free Report ) reported marginal growth in assets under management (AUM) as of Oct 31, 2019, from the previous month. Preliminary month-end AUM came in at $791 …

Zacks Investment Research

Invest in These 5 Low Leverage Stocks Before Q4 Earnings | Zacks | 1/13/2020

Invest in These 5 Low Leverage Stocks Before Q4 Earnings Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read … Research Wizard today . Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this …

HCA Healthcare Acquires Valify to Rein in Medical Costs | Zacks | 1/13/2020

HCA Healthcare Acquires Valify to Rein in Medical Costs Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More … LLC; Investor’s Business Daily, Inc.; and Morningstar, Inc. Copyright 2020 Zacks Investment Research 10 S Riverside Plaza Suite 1600 Chicago, IL 60606 At the center of everything we do is a strong commitment to independent …

HSBC Holdings

The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody’s | 11/18/2019

Read More Hide Full Article For Immediate Release Chicago, IL – November 18, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron ( CVX - Free Report ) , HSBC Holdings ( HSBC - Free Report ) , Sanofi ( SNY - Free Report ) , Sony ( SNE - Free Report ) and Moody’s ( MCO …

The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, HSBC, PetroChina and Netflix | 10/21/2019

Read More Hide Full Article For Immediate Release Chicago, IL –October 21, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Facebook ( FB - Free Report ) , UnitedHealth ( UNH - Free Report ) , HSBC Holdings ( HSBC - Free Report ) , PetroChina ( PTR - Free Report ) and Netflix ( NFLX …

Morgan Stanley

GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day | 11/14/2019

GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day Zacks Equity Research You follow Press Releases - edit You follow Zacks Equity Research - edit What would you like to … for in Street estimates. PT lowered from $228 to $215. Morgan Stanley: Analyst David Lebowitz said GW Pharmaceuticals’ U.S. Epidiolex sales of about $86M in Q3 “ultimately is a strong number that supports long-term …

The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences | 10/23/2019

Read More Hide Full Article For Immediate Release Chicago, IL – October 23, 2019, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: U.S. Bancorp ( USB - Free Report ) , Bristol-Myers Squibb ( BMY - Free Report ) , Morgan Stanley ( MS - Free Report ) , Bank of America …

Goldman Sachs

U.S. Bancorp Announces Additional Share Buyback of Up to $2.5B | Zacks | 11/13/2019

U.S. Bancorp Announces Additional Share Buyback of Up to $2.5B Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read … of America ( BAC - Free Report ) , JPMorgan ( JPM - Free Report ) and Goldman Sachs ( GS - Free Report ) .Alongside share repurchase, the company is also active in dividend payments. Since 2011, U.S. Bancorp has been raising its dividend …

The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle | 11/12/2019

… Release Chicago, IL –November 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … its own development bank. It’s been a long road since Goldman Sachs’ analyst Jim O’Neill coined the term BRIC in 2001 to describe a grouping of the four biggest emerging markets. The term has evolved …

T. Rowe Price

T. Rowe Price Reports 1.8% Sequential Rise in October AUM | Yahoo News | 11/13/2019

T. Rowe Price Reports 1.8% Sequential Rise in October AUM Zacks Equity Research Reblog T. Rowe Price Group, Inc. TROW has announced preliminary assets under management (AUM) of $1.15 trillion for October 2019. Results reflect nearly 1.8% rise from the $1.13 trillion recorded as of Sep 30, 2019.Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $1.1 billion in October.Month-end total sponsored U.S …

U.S. Bancorp

U.S. Bancorp Announces Additional Share Buyback of Up to $2.5B | Zacks | 11/13/2019

U.S. Bancorp Announces Additional Share Buyback of Up to $2.5B Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article U.S. Bancorp ( USB - Free Report ) recently announced an additional share-repurchase program of up to $2.5 billion, following the Fed’s approval.This adds to June’s buyback authorization of up to $3 billion …

The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences | 10/23/2019

Read More Hide Full Article For Immediate Release Chicago, IL – October 23, 2019, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: U.S. Bancorp ( USB - Free Report ) , Bristol-Myers Squibb ( BMY - Free Report ) , Morgan Stanley ( MS - Free Report ) , Bank of America …

Blackstone Group

Aflac Acquires Argus, Expands U.S. Segment Product Suite | Zacks | 11/11/2019

Aflac Acquires Argus, Expands U.S. Segment Product Suite Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … 2017, Aflac acquired HealthMarkets Insurance Company from HealthMarkets LLC, a Blackstone Group LP company. The Argus acquisition is unlikely to have any material impact on the company’s 2019 earnings. Year to date, the stock has …

Blackstone & Others Sued for Faulty Investment Advice to KRS | Zacks | 12/28/2017

Blackstone & Others Sued for Faulty Investment Advice to KRS Zacks Equity Research Trades from $ 3 Read More Hide Full Article KKR & Co. L.P. ( KKR - Free Report ) , The Blackstone Group L.P. ( BX - Free Report ) and PAAMCO along with their founders have been accused of violating their fiduciary duty to the Kentucky Retirement Systems pension fund by giving the fund wrong investment advice.Recently, a few Kentucky state workers filed a lawsuit against …

HMS Holdings

HMS Holdings (HMSY) Surpasses Q3 Earnings Estimates | Yahoo News | 11/1/2019

HMS Holdings (HMSY) Surpasses Q3 Earnings Estimates Zacks Equity Research Reblog HMS Holdings (HMSY) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this benefits coordinator …

Citigroup

The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy | 11/1/2019

Read More Hide Full Article For Immediate Release Chicago, IL –November 1, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Citigroup ( C - Free Report ) , Novo Nordisk ( NVO - Free Report ) , BP ( BP - Free Report ) , salesforce.com ( CRM - Free Report ) and TC Energy …

The Zacks Analyst Blog Highlights: Advanced Micro Devices, Ambarella, NRG Energy and Entergy | Yahoo News | 10/30/2019

The Zacks Analyst Blog Highlights: Advanced Micro Devices, Ambarella, NRG Energy and Entergy Zacks Equity Research Reblog For Immediate Release Chicago, IL – October 30, 2019 – Zacks.com announces the list of stocks featured in the Analyst … of the country’s biggest banks like Bank of America and Citigroup has slowed in third-quarter 2019 as compared to the prior quarter, JPMorgan has witnessed a drop in lending. Thus, the Federal Reserve’s recent …

LHC Group

LHC Group (LHCG) Is Up 3.04% in One Week: What You Should Know | Zacks | 1/20/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Momentum investing revolves around the idea of … this issue for us. Below, we take a look at LHC Group ( LHCG - Free Report ) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum …

Teladoc to Buy InTouch Health, Expand Reach in Virtual Care | Zacks | 1/13/2020

Teladoc to Buy InTouch Health, Expand Reach in Virtual Care Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read … in the same space are HealthEquity, Inc. ( HQY - Free Report ) , LHC Group, Inc. ( LHCG - Free Report ) and OpGen, Inc. ( OPGN - Free Report ) . While HealthEquity and LHC Group sport a Zacks Rank 1 (Strong Buy), Natera …

Genesis Healthcare

Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings | Zacks | 11/18/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Humana Inc. ( HUM - Free Report ) hit a … Free Report ) , WellCare Health Plans, Inc. ( WCG - Free Report ) and Genesis Healthcare, Inc. ( GEN - Free Report ) . You can see the complete list of today’s Zacks 1 Rank (Strong Buy) stocks here. Select Medical Holdings operates …

Genesis Healthcare (GEN) Dips More Than Broader Markets: What You Should Know | Zacks | 10/31/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Genesis Healthcare ( GEN - Free Report ) closed the most recent trading day at $1.28, moving -0.78% from the previous trading session. This move lagged the S&P 500’s daily loss of 0.3%. Elsewhere, the Dow lost 0.52%, while the tech-heavy Nasdaq …

HCA

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative | Zacks | 11/13/2019

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … plans. The company’s rating is further cushioned by customer diversity, healthcare services that are outsourcing market trends, liquidity level and buyouts.The company’s Speculative Grade Liquidity -1 Rating supports Moody’s expectation for MEDNAX to maintain solid …

Looking for Value? Why It Might Be Time to Try HCA Healthcare (HCA) | Zacks | 11/11/2019

Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; HCA Healthcare, Inc …

Tenet Healthcare

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative | Zacks | 11/13/2019

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … better-ranked stocks like HCA Healthcare, Inc. ( HCA - Free Report ) , Tenet Healthcare Corporation ( THC - Free Report ) and WellCare Health Plans, Inc. ( WCG - Free Report ) . You can see the complete list of today’s Zacks 1 Rank …

The Zacks Analyst Blog Highlights: McGrath RentCorp, FTI Consulting, Huron Consulting, Select Medical and Tenet Healthcare | 11/7/2019

Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: McGrath RentCorp ( MGRC - Free Report ) , FTI Consulting Inc. ( FCN - Free Report ) , Huron Consulting Group Inc. ( HURN - Free Report ) , Select Medical Holdings Corp. ( SEM - Free Report ) and Tenet Healthcare Corp. ( THC - Free Report ) . Here are highlights from Wednesday’s Analyst Blog: ISM Services Rebound in October: 5 Top-Ranked …

HCA Healthcare

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative | Zacks | 11/13/2019

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … can take a look at some better-ranked stocks like HCA Healthcare, Inc. ( HCA - Free Report ) , Tenet Healthcare Corporation ( THC - Free Report ) and WellCare Health Plans, Inc. ( WCG - Free Report ) . You can see the complete …

Looking for Value? Why It Might Be Time to Try HCA Healthcare (HCA) | Zacks | 11/11/2019

Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; HCA Healthcare, Inc …

DaVita Medical Group

What’s in the Cards for DaVita (DVA) This Earnings Season? | Zacks | 11/4/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article DaVita Inc. ( DVA - Free Report ) is scheduled to release … be-reported quarter.For investors’ notice, the company has divested the DaVita Medical Group unit to Optum for $4.3 billion. This is expected to enhance DaVita’s focus on its core Kidney Care business. Notably, the Kidney …

UnitedHealth (UNH) Closes DaVita Unit Buy, Expands OptumCare - Nasdaq.com | 6/26/2019

UnitedHealth (UNH) Closes DaVita Unit Buy, Expands OptumCare June 26, 2019, 06:12:00 PM EDT By Zacks Equity Research, Zacks.com Shutterstock photo UnitedHealth Group Inc. ‘s UNH Optum unit has completed the buyout of DaVita Medical Group, a unit of DaVita Inc. DVA , for $4.3 billion in cash. This acquisition has been made by OptumCare - a sub-segment of Optum - the company’s health services segment. OptumCare provides primary and urgent care …

WellCare Health

Why Hold Strategy is Apt for Universal Health (UHS) Now | Zacks | 1/16/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Universal Health Services Inc. ( UHS - Free Report ) is well … ranked stocks like The Ensign Group, Inc. ( ENSG - Free Report ) , WellCare Health Plans, Inc. ( WCG - Free Report ) and The Joint Corp. ( JYNT - Free Report ) .Ensign Group provides health care services in the post-acute care …

Why Should You Retain MEDNAX (MD) Stock in Your Portfolio? | Zacks | 1/15/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article MEDNAX Inc. ( MD - Free Report ) has been in investors … some better-ranked stocks like Humana Inc. ( HUM - Free Report ) , WellCare Health Plans, Inc. ( WCG - Free Report ) and The Joint Corp. ( JYNT - Free Report ) .Humana operates as a health and well-being company in the …

Wellcare

Why WellCare (WCG) is Poised to Beat Earnings Estimates Again | Zacks | 1/14/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? WellCare Health Plans ( WCG - Free Report ) , which belongs to the Zacks Medical - HMOs industry, could be …

WellCare (WCG) Hits 52-Week High, Can the Run Continue? | Zacks | 1/9/2020

You follow 52 Week High - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Have you been paying attention to shares of WellCare Health Plans ( WCG - Free Report ) ? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $336.63 in the previous session …

Humana

Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings | Zacks | 11/18/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Humana Inc. ( HUM - Free Report ) hit a fresh 52-week high of $340.48 on Nov 15, before closing the day at $335.55. Impressive earnings performance in the third quarter and solid Medicare business contributed to this rally.Over the past year, the Zacks …

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co | 11/8/2019

… Release Chicago, IL – November 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … war woes, healthcare companies have raked in gains. Companies like Humana, CVS Health Corp, DaVita have posted stellar third-quarter earnings and their shares have jumped 3.5%, 5.6% and 12.9%, respectively, since reporting earnings. Our …

Wellcare Health Plans

Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings | Zacks | 11/18/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Humana Inc. ( HUM - Free Report ) hit a … ranked stocks like Select Medical Holdings Corporation ( SEM - Free Report ) , WellCare Health Plans, Inc. ( WCG - Free Report ) and Genesis Healthcare, Inc. ( GEN - Free Report ) . You can see the complete list of today’s Zacks 1 Rank …

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative | Zacks | 11/13/2019

MEDNAX’s Ratings Get Affirmed by Moody’s, Outlook Negative Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … HCA - Free Report ) , Tenet Healthcare Corporation ( THC - Free Report ) and WellCare Health Plans, Inc. ( WCG - Free Report ) . You can see the complete list of today’s Zacks 1 Rank stocks here. HCA Healthcare provides health care …

Aetna

CVS Health’s New Plans With Aetna May Improve Health Outcomes | MSN | 11/15/2019

CVS Health’s New Plans With Aetna May Improve Health Outcomes Zacks Equity Research 14 hrs ago Zacks Equity Research CVS, with its newly-acquired Aetna business, developed a Social Isolation Index to assess each Medicare beneficiary’s risk of social isolation. The mentioned index is based on claims data and multifaceted data on social determinants of health, and will help in identifying high-risk candidates. The company’s outreach program, Resources For …

Here’s Why You Should Hold on to CVS Health (CVS) For Now | Zacks | 11/14/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article CVS Health ( CVS - Free Report ) has been gaining from … Potential : Following the $70-billion acquisition of health insurance giant, Aetna, CVS Health has introduced a business arm called Health Care Benefit. This segment has started to pick up momentum, particularly in government business. In …

UnitedHealthcare

UnitedHealth (UNH) Up 7% Since Last Earnings Report: Can It Continue? | Zacks | 11/14/2019

You follow Realtime BLOG - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article It has been about a month since the last … 13.8% year over year. Higher revenues, strength in both segments — UnitedHealthcare and Optum — plus membership growth led to this outperformance. Strong Operating Performance UnitedHealth posted revenues of $60.4 billion, beating the Zacks Consensus Estimate by …

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health | Yahoo News | 11/11/2019

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health Zacks Equity Research Reblog For Immediate Release Chicago, IL – November 11, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog … the back of higher revenues, and strength in both segments, UnitedHealthcare and Optum. However, slowdown of growth in international operations and underperformance in Medicaid business are some concerns. Merck ’s shares have declined 1.9% over …

Magellan Health

Magellan Health (MGLN) Lags Q3 Earnings Estimates | Zacks | 11/1/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Magellan Health ( MGLN - Free Report ) came out with quarterly earnings of $1.23 per share, missing the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.45 per share a year ago. These figures are adjusted for non-recurring items …

Magellan Health (MGLN) to Post Q2 Earnings: What’s in Store? | Nasdaq | 7/26/2019

Magellan Health (MGLN) to Post Q2 Earnings: What’s in Store? July 26, 2019, 12:09:00 PM EDT By Zacks Equity Research, Zacks.com Shutterstock photo Magellan Health, Inc. MGLN is set to report second-quarter 2019 earnings results on Jul 30. The Zacks Consensus Estimate for earnings in the to-be-reported quarter is 83 cents per share on revenues of $1.74 billion, which translates into year-over-year decline of 9.78 …

Cigna

MetLife (MET) Q3 Earnings Miss, Revenues Beat Estimates | Yahoo News | 10/31/2019

MetLife (MET) Q3 Earnings Miss, Revenues Beat Estimates Zacks Equity Research MetLife, Inc. ’s MET third-quarter 2019 operating earnings of $1.27 per share missed the Zacks Consensus Estimate by 9.93%. The bottom line declined 8% year over year. Earnings suffered from increase in expenses, which offset revenue growth. Cigna Corporation Price, Consensus and EPS Surprise Cigna Corporation Price, Consensus and EPS Surprise More Cigna Corporation price-consensus-eps-surprise …

Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth | Zacks | 10/24/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Cigna ( CI - Free Report ) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2019. This widely-known consensus outlook gives a good sense of the company’s earnings picture …

Molina Healthcare

Healthcare Stock Earnings Slated on Oct 29: HCA, MOH & More | Zacks | 10/28/2019

You follow Analyst Blog: Earnings Preview - ESP - edit You follow Zacks Equity Research - Zacks Equity Research Cancel The healthcare industry, which is part of the medical sector, is likely to have witnessed a favorable performance … HCA Healthcare, Inc. price-eps-surprise HCA Healthcare, Inc. Quote Molina Healthcare Inc. ( MOH - Free Report ) is a multi-state managed care organization participating exclusively in government-sponsored healthcare programs such as the Medicaid program …

What to Expect for Universal Health’s (UHS) Q3 Earnings | Zacks | 10/21/2019

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Universal Health Services, Inc. ( UHS - Free Report ) is set … has an Earnings ESP of +0.55% and is Zacks 3 Ranked.Molina Healthcare, Inc ( MOH - Free Report ) is set to report third-quarter earnings on Oct 29. The stock has a Zacks Rank of 1 and …

Warren Buffett

When Does Market Timing Actually Work? - February 05, 2020 | Zacks | 2/5/2020

You follow Retirement Ideas - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Being that unique investor who has the power to … storm, or even better, milk the opportunity to buy low. Warren Buffett has made his fortune based off this simple rule. He benefits by focusing on the long - term and buying high quality stocks at …

The Truth About Market Timing - November 14, 2019 | Zacks | 11/14/2019

You follow Retirement Ideas - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Being that unique investor who has the power to … sell amid little crashes - instead exploit the opportunity by buying. Warren Buffett has made a great part of his fortune due to this simple rule. He cautions not to sell during little crashes, and encourages …

Warren Buffet

When Does Market Timing Actually Work? - February 05, 2020 | Zacks | 2/5/2020

You follow Retirement Ideas - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Being that unique investor who has the power to … approach that has been used successfully by astute investors like Warren Buffet. Rule 1: Never attempt and time tops and bottoms. Forget tracking for market tops or bottoms to expand your odds for success with …

The Truth About Market Timing - November 14, 2019 | Zacks | 11/14/2019

You follow Retirement Ideas - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Being that unique investor who has the power to … that has been utilized effectively by insightful financial specialists like Warren Buffet for a considerable length of time. Rule 1: Never try and time tops and bottoms. Abandoning the objective to time the tops and …

Jerome Powell

The Zacks Analyst Blog Highlights: Enphase Energy, Brookfield Business Partners, Amedisys, Pure Storage and Match Group | 1/27/2020

… Release Chicago, IL – January 27, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … consecutive times last year to stimulate the economy. Fed Chair Jerome Powell had said that there is no immediate need to hike the federal fund’s rate unless there is a constant rise in inflation. Some …

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences | 1/10/2020

… Release Chicago, IL – January 10, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … consecutive times last year to stimulate the economy. Fed Chair Jerome Powell had said that there is no immediate need to increase the federal fund’s rate unless there is a constant rise in inflation. Coming …

Mark Cuban

The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys | 1/24/2020

… Release Chicago, IL –January 24, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for regular investors who make the right …

The Zacks Analyst Blog Highlights: Chevron, Netflix, NextEra, IBM and HCA | 1/24/2020

… Release Chicago, IL –January 24, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for regular investors who make the right …

Lamb Weston

Lamb Weston (LW) Up 0.2% Since Last Earnings Report: Can It Continue? | Zacks | 11/1/2019

You follow Realtime BLOG - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article A month has gone by since the last earnings report for Lamb Weston ( LW - Free Report ) . Shares have added about 0.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or …

Lamb Weston Forms JV in Argentina, Expansion Plans on Track | Zacks | 10/16/2019

Lamb Weston Forms JV in Argentina, Expansion Plans on Track Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Lamb Weston Holdings, Inc. ( LW - Free Report ) has been striving to boost revenues through prudent partnerships and acquisitions. Per latest developments, the company announced a joint venture (JV) with Sociedad Comercial …

Christine Lagarde

The Zacks Analyst Blog Highlights: Taiwan Semi, Target and D.R. Horton | Yahoo News | 10/22/2019

The Zacks Analyst Blog Highlights: Taiwan Semi, Target and D.R. Horton Zacks Equity Research Reblog For Immediate Release Chicago, IL – October 22, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every … his last European Central Bank meeting before handing over to Christine Lagarde, and policy setters gather in Norway and Sweden. That happens on Thursday. A more volatile Turkey will also set rates. There are many …